In the News

ACE inhibitors improved all-cause mortality, cardiovascular outcomes versus ARBs

Angiotensin-converting enzyme (ACE) inhibitors improved all-cause mortality, cardiovascular mortality, and major cardiovascular events compared with angiotensin II receptor blockers (ARBs) in patients with diabetes, a new study found.

Studies suggest no elevated risk of pancreatitis with incretin-based drugs

A study and a meta-analysis suggest incretin-based drugs don't increase the risk of pancreatitis in patients with type 2 diabetes.

Novel algorithms could help individualize HbA1c goals

Two novel algorithms to individualize glycemic control targets would allow clinicians to set HbA1c goals, reclassify from one-quarter to one-third of patients as controlled instead of uncontrolled, and possibly improve treatment of certain patient populations, a study found.

MKSAP quiz: Checking kidney function

This month's quiz asks readers to evaluate a 59-year-old woman recently diagnosed with type 2 diabetes mellitus and hyperlipidemia during a routine follow-up visit.

Albuminuria can be ruled out with quantitative point-of-care tests

To screen at-risk patients for albuminuria, quantitative tests can be used effectively at the point of care, but semiquantitative tests are not sufficiently accurate, a recent meta-analysis found.

Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria

In a trial of more than 1,000 diabetic patients with proteinuria, adding an ACE inhibitor to an ARB didn't improve estimated glomerular filtration rate and increased risk for hyperkalemia and acute kidney injury, so the trial was halted early.

Patients with pumps

As insulin pumps become more common, hospitalists need plans to manage them. Learn about the issues that can arise, including potentially difficult negotiations with patients, in the April ACP Hospitalist.

New GLP-1 receptor agonist approved

Albiglutide (Tanzeum), a glucagon-like peptide-1 (GLP-1) receptor agonist, was recently approved by the FDA to treat type 2 diabetes in adults, along with diet and exercise.

Spotlight on trends in diabetes prevalence and outcomes

Several recent analyses of national health care data assessed the prevalence of diabetes and its complications in the U.S.